NCT01285752已完成2 期
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 240
研究概览
简要总结
To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of RA (class I to III)
- •Stable dose of methotrexate (at least 12 weeks)
排除标准
- •Pregnant or breastfeeding
- •Abnormal screening laboratory test values considered to be clinically significant
研究组 & 干预措施
1
Experimental
干预措施: AK106-001616 (Drug)
2
Experimental
干预措施: AK106-001616 (Drug)
3
Active Comparator
干预措施: Active comparator (Drug)
研究者
相似试验
已完成
2 期
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00902369Asahi Kasei Pharma Corporation130
已完成
2 期
A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00520572AstraZeneca385
已完成
4 期
Objective Study in Rheumatoid ArthritisArthritis, RheumatoidNCT00451971Sanofi249
已完成
3 期
A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KArthritis, RheumatoidNCT01638013Astellas Pharma Inc843
已完成
2 期
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's DiseaseHuntington DiseaseNCT00724048Teva Branded Pharmaceutical Products R&D, Inc.227